Safety and pharmacokinetics of novel selective vascular endothelial growth factor receptor-2 inhibitor YN968D1 in patients with advanced malignancies

Table 4 Response Evaluation for Each Dose Cohort

Dose Cohort	Response in evaluable patient (n = 37)				Disease control (%)
	CR	PR	SD	PD	CR+PR+SD
250 mg	0	1	1	1	2 (66.7)
500 mg	0	2	4	3	6 (66.7)
750 mg	0	2	9	0	11 (100)
850 mg	0	2	8	1	10 (90.9)
1000 mg	0	0	2	1	2 (66.7)
Total	0	7	24	6	31 (83.8)

Abbreviations: CR, complete response; PR, partial response; SD, stable disease; PD, progressive disease.

ISSN: 1471-2407